NCT06747728
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
Recruiting · Not Applicable · The First Affiliated Hospital of Zhengzhou University · registry updated 2024-12-24
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the GBM patient.GBM histologically appears to be a tumor of vascular origin characterized by necrosis and microvascular proliferation, and neoangiogenesis is a key factor in the growth and poor prognosis of GBM. Bevacizumab can inhibit the biological effects of VEGF, including the permeability and proliferation of blood vessels, as well as the migration and survival of endothelial cells, so as to inhibit tumor angiogenesis, growth and metastasis. The aim of this study is to evaluate the efficacy and safety of bevacizumab in the preoperative adjuvant treatment of patients with new-onset high-grade gliomas.
Inclusion
- Age ≥ 18 years.
- Male or female.
- Imaging diagnosis of high-grade glioma.
- KPS score ≥60.
Exclusion
- Prior treatment with anti-angiogenic targeted drugs;
- Comorbid serious cardiac, pulmonary, hepatic, or renal disease;
- History of an arterial/venous thrombotic event within 6 months prior to screening;
- Combination of infectious diseases such as tuberculosis and viral hepatitis;
- Comorbid infectious diseases such as tuberculosis, viral hepatitis, uncontrolled high blood pressure, bleeding disorders, and long-standing unhealed wounds or incompletely healed fractures;
- Patients with a history of psychotropic substance abuse that cannot be stopped or patients with mental disorders;